[1]侯毅翰,许中.头孢他啶阿维巴坦对抗感染治疗患者53例疗效的影响因素分析[J].福建医药杂志,2021,43(06):18-21.
　HOU Yihan,XU Zhong.Analysis of the clinical influencing factors of ceftazidime-avibactam for 53 anti-infection patients[J].FUJIAN MEDICAL JOURNAL,2021,43(06):18-21.
点击复制

头孢他啶阿维巴坦对抗感染治疗患者53例疗效的影响因素分析()
分享到：

《福建医药杂志》[ISSN:1002-2600/CN:35-1071/R]

卷:
43
期数:
2021年06期
页码:
18-21
栏目:
临床研究
出版日期:
2021-12-15

文章信息/Info

Title:
Analysis of the clinical influencing factors of ceftazidime-avibactam for 53 anti-infection patients
文章编号:
1002-2600(2021)06-0018-04
作者:
侯毅翰; 许中1
厦门大学附属第一医院(厦门 361000)
Author(s):
HOU Yihan;  XU Zhong
The First Affiliated Hospital of Xiamen University,Xiamen,Fujian 361000,China
关键词:
头孢他啶阿维巴坦;  抗感染治疗;  疗效;  影响因素
Keywords:
ceftazidime-avibactam;  anti-infection therapy;  clinical effect;  influencing factor
分类号:
R453.2
文献标志码:
B
摘要:
目的 探讨头孢他啶阿维巴坦疗效的影响因素。方法 将我院53例使用头孢他啶阿维巴坦抗感染治疗的住院患者根据其病原微生物的监测结果分为目标性抗感染治疗组(目标组)和经验性抗感染治疗组(经验组),采用回顾性分析总结相关临床资料,比较两组间各个因素的差异,并对两组间有差异的因素进行logistic回归分析。结果 组内比较,两组患者治疗后的体温、降钙素原(PCT)、C反应蛋白(CRP)、白介素-6(IL-6)都较治疗前差异具有统计学意义(P<0.05),而脑利钠肽(BNP)差异无统计学意义(P>0.05); 组间比较,治疗后两组患者间的体温、PCT、CRP差异具有统计学意义(P<0.05)。两组在多发感染、粒细胞减少、恶性肿瘤(含血液系统恶性肿瘤)、接受器官或组织移植、建立人工气道、使用激素方面差异存在统计学意义(P<0.05)。logistic回归分析中,结果发现,粒细胞减少和恶性肿瘤(含血液系统恶性肿瘤)可能是头孢他啶阿维巴坦疗效的影响因素。结论 虽然头孢他啶阿维巴坦在目标性与经验性抗感染上均显示出良好的疗效,但在一定程度上前者优于后者。粒细胞减少和恶性肿瘤(含血液系统恶性肿瘤)可能影响头孢他啶阿维巴坦经验性抗感染治疗的效果。
Abstract:
Objective To analyze the clinical influencing factors of ceftazidime-avibactam for anti-infection patients. Methods A total of 53 patients in our hospital who were treated with ceftazidime-avibactam were divided into targeted anti-infection group(targeted group)and empirical anti-infection group(empirical group)according to the test of pathogen microbes. The clinical data was summarized by retrospective method.The differences of various factors between the two groups were compared,and the factors with differences between the two groups were analyzed by logistic regression.Results Compared with the data before treating with ceftazidime-avibactam,the temperature,procalcitonin(PCT),C-reactive protein(CRP),interleukin-6(IL-6)were statistically significant after treating with ceftazidime-avibactam in both groups(P<0.05),but brain natriuretic peptide(BNP)was not statistically significant(P>0.05). After treating with ceftazidime-avibactam, the temperature, PCT, and CRP were statistically significant between the two groups(P<0.05). The differences of polyinfection, granulocytopenia, malignant tumor including hematological malignancies, organ or tissue transplantation, intubation of the artificial airway and using glucocorticoid were statistically significant between the two groups(P<0.05). In logistic regression analysis,the results showed that granulocytopenia and malignant tumor including hematological malignancies may be the influencing factors of ceftazidime-avibactam for anti-infection patients. Conclusion Although ceftazidime-avibactam displays excellent efficacy both in targeted and empirical anti-infection treatment,but the former is better than the later to some extent. Granulocytopenia and malignant tumor including hematological malignancies may be the influencing factors of ceftazidime-avibactam for anti-infection patients in the empirical treatment.

参考文献/References:

[1] Cira M,Echeverria-Palencia C M,Callejas I,et al.Commercially available garden products as important sources of antibiotic resistance genes-a survey[J].Environ Sci Pollut Res Int,2021,28(32):43507-43514.
[2] Wang Y N,Lyu N,Liu F,et al.More diversified antibiotic resistance genes in chickens and workers of the live poultry markets[J].Environ Int,2021,153:106534.
[3] Plaza-Rodríguez C,Alt K,Grobbel M,et al.Wildlife as Sentinels of Antimicrobial Resistance in Germany?[J].Front Vet Sci,2021,7:627821.
[4] Jewell M J,Leyenaar J,Shieh M S,et al.Unnecessary antibiotic prescribing in children hospitalised for asthma exacerbation:a retrospective national cohort study[J].BMJ Qual Saf,2021,30(4):292-299.
[5] 国家卫生健康委合理用药专家委员会,全国细菌耐药监测网.2019年全国细菌耐药监测报告[J].中国合理用药探索,2021,18(3):1-11.
[6] Koeth L M,Matuschek E,Kahlmeter G,et al.Development of EUCAST zone diameter breakpoints and quality control criteria for ceftazidime-avibactam 10-4 ug[J].Eur J Clin Microbiol Infect Dis,2018,37(6):1047-1053.
[7] Clerici D,Oltolini C,Greco R,et al.The place of ceftazi-dime/avibactam and ceftolozane/tazobactam for therapy of haematological patients with febrile neutropenia[J].Int J Antimicrob Agents,2021,57(6):106335.
[8] 闫晨华,徐婷,郑晓云,等.中国血液病患者中性粒细胞缺乏伴发热的多中心、前瞻性流行病学研究[J].中华血液学杂志,2016,37(3):177-182.
[9] 中华医学会血液学分会,中国医师协会血液科医师分会.中国中性粒细胞缺乏伴发热患者抗菌药物临床应用指南(2020年版)[J].中华血液学杂志,2020,41(12):969-978.
[10] 徐春晖,宿扬,吕燕霞,等.肛周皮肤拭子细菌培养对血液病患者耐碳青霉烯类肠杆菌血流感染的预警价值[J].中华血液学杂志,2018,39(12):1021-1025.
[11] Zheng C C,Tang B L,Zhu X Y,et al.Pre-engraftment bloodstream infections in acute leukemia patients undergoing unrelated cord blood transplantation following intensified myeloablative conditioning without ATG[J].Ann Hematol, 2017,96(1):115-124.
[12] Zaragoza R, Vidal-Cortés P, Aguilar G, et al.Update of the treatment of nosocomial pneumonia in the ICU[J].Crit Care,2020,24(1):383.
[13] Tumbarello M,Trecarichi E M,Corona A,et al.Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by Klebsiella pneumoniae Carbapenemase-producing K.pneumoniae[J].Clin Infect Dis,2019,68(3):355-364.
[14] Abdel-Azim H,Sun W L,Wu L T.Strategies to generate functionally normal neutrophils to reduce infection and infection-related mortality in cancer chemotherapy[J].Pharmacol Ther,2019,204:107403.

备注/Memo

备注/Memo:
1 通信作者,Email:22469158@qq.com
更新日期/Last Update: 2021-12-15